| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
The primary target of (-)-corypalmine is bacteria, against which it exhibits antimicrobial activity. The compound is a naturally occurring alkaloid with antimicrobial effects. The precise molecular targets and mechanisms of action have not been fully elucidated but may involve disruption of bacterial cell processes. Further studies are needed to identify its specific molecular targets.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that (-)-corypalmine possesses antimicrobial activity. The compound has been isolated from Guatteriopsis friesiana and shown to have antimicrobial effects. Specific IC₅₀ or MIC values have not been extensively reported in the available literature. The compound's in vitro activity supports its potential for further investigation as an antimicrobial agent.
|
| ln Vivo |
In vivo activity of (-)-corypalmine has not been extensively reported. The compound is primarily used as a research tool for in vitro studies of antimicrobial activity. Animal model studies evaluating its in vivo efficacy have not been published. Further investigations are needed to assess its therapeutic potential.
|
| Enzyme Assay |
For antimicrobial activity screening, standard agar diffusion or broth microdilution methods are used. Bacteria such as Staphylococcus aureus and Escherichia coli are cultured on appropriate media and exposed to serial dilutions of (-)-corypalmine. MIC values are determined after 24-48 hours of incubation. Standard protocols for antimicrobial activity testing are described in the literature.
|
| Cell Assay |
For in vitro cell-based studies, bacterial cells are cultured in appropriate media and treated with serial dilutions of (-)-corypalmine. Bacterial growth is assessed by measuring optical density or colony counting. Cell viability is assessed using standard assays. Cytotoxicity against mammalian cells may be assessed in parallel.
|
| Animal Protocol |
In vivo animal studies for (-)-corypalmine have not been extensively reported. For similar antimicrobial alkaloids, mouse models of bacterial infection may be used. The compound would be administered via oral or intraperitoneal routes. Efficacy endpoints include reduction in bacterial burden and survival. Standard protocols for in vivo efficacy studies can be adapted from the literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of (-)-corypalmine have not been comprehensively characterized. As an alkaloid with a molecular weight of 341.40 g/mol, it is expected to have reasonable membrane permeability. The compound is typically stored as a powder at -20°C. Specific PK parameters such as half-life, clearance, and bioavailability have not been reported. Further pharmacokinetic studies are needed.
|
| Toxicity/Toxicokinetics |
Toxicological data for (-)-corypalmine are limited. As a natural alkaloid, it may have a favorable safety profile. However, systematic toxicological studies have not been extensively published. The compound is for research use only and is not intended for human therapeutic use. Standard safety assessments would be needed for therapeutic development.
|
| References | |
| Additional Infomation |
(+)-corydin has been reported in plants of the genus Corydalis, yellow false tobacco, and other organisms with available data.
(-)-Corypalmine is a research compound used in studies of isoquinoline alkaloids and their biological activities. It is isolated from Guatteriopsis friesiana. The compound has antimicrobial activity. No clinical trials or therapeutic applications have been reported. (-)-Corypalmine serves as a research tool for studying alkaloid pharmacology and antimicrobial mechanisms. |
| Molecular Formula |
C20H23NO4
|
|---|---|
| Molecular Weight |
341.40
|
| Exact Mass |
341.162
|
| CAS # |
6018-40-2
|
| Related CAS # |
Corypalmine;27313-86-6
|
| PubChem CID |
12304090
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
501.2±50.0 °C at 760 mmHg
|
| Flash Point |
256.9±30.1 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.640
|
| LogP |
2.93
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
25
|
| Complexity |
461
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O(C([H])([H])[H])C1=C(C([H])=C([H])C2=C1C([H])([H])N1C([H])([H])C([H])([H])C3=C([H])C(=C(C([H])=C3[C@@]1([H])C2([H])[H])OC([H])([H])[H])O[H])OC([H])([H])[H]
|
| InChi Key |
BMCZTYDZHNTKPR-MRXNPFEDSA-N
|
| InChi Code |
InChI=1S/C20H23NO4/c1-23-18-5-4-12-8-16-14-10-19(24-2)17(22)9-13(14)6-7-21(16)11-15(12)20(18)25-3/h4-5,9-10,16,22H,6-8,11H2,1-3H3/t16-/m1/s1
|
| Chemical Name |
(13aR)-2,9,10-trimethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinolin-3-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9291 mL | 14.6456 mL | 29.2912 mL | |
| 5 mM | 0.5858 mL | 2.9291 mL | 5.8582 mL | |
| 10 mM | 0.2929 mL | 1.4646 mL | 2.9291 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
